Abvc Biopharma (ABVC) Tax Provisions (2016 - 2026)
Abvc Biopharma's (ABVC) quarterly Tax Provisions came in at -$170201.0 in Q2 2026, down 820.37% on a YoY basis from $23627.0 in Q2 2025, and up 52.04% quarter-over-quarter from -$354887.0 in Q1 2026.
Powered by 
Analysis
Abvc Biopharma (ABVC) Tax Provisions (2016 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has reported Tax Provisions for 11 consecutive years, with -$170201.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Tax Provisions fell 820.37% year-over-year to -$170201.0; the trailing twelve-month figure through Jun 2026 stood at -$524561.0 (down 201.32% YoY), and the FY2025 full-year result was $24154.0, up 121.85% from the prior year.
- Tax Provisions improved to -$170201.0 in Q2 2026 per ABVC's latest filing, from -$354887.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $962874.0 in Q4 2022 and bottomed at -$354887.0 in Q1 2026.
- Historically, Tax Provisions has averaged $17445.7 across 5 years, with a median of -$322.0 in 2023.
- The sharpest annual moves came in 2023 and 2026: Tax Provisions soared 199.08% in 2023, then sank 820.37% in 2026.
- Over 5 years, Tax Provisions stood at $962874.0 in 2022, then slumped by 81.79% to $175310.0 in 2023, then sank by 99.8% to $355.0 in 2024, then soared by 48.45% to $527.0 in 2025, then plunged by 32396.2% to -$170201.0 in 2026.
- According to Business Quant data, Tax Provisions over the past three periods registered -$170201.0, -$354887.0, and $527.0 for Q2 2026, Q1 2026, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 393.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 242.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 292.00 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 230.90 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -59.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 15.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 34.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -3.96 Mn |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | -170,201.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -170,201.00 |
| Mar 31, 2026 | -354,887.00 |
| Sep 30, 2025 | 527.00 |
| Jun 30, 2025 | 23,627.00 |
| Mar 31, 2025 | -198,071.00 |
| Sep 30, 2024 | 355.00 |
| Jun 30, 2024 | -110,894.00 |
| Dec 31, 2023 | 175,310.00 |
| Sep 30, 2023 | -999.00 |
| Jun 30, 2023 | 81,695.00 |
| Dec 31, 2022 | 962,874.00 |
| Sep 30, 2022 | 4,222.00 |
| Jun 30, 2022 | -82,451.00 |
| Mar 31, 2022 | -86,867.00 |
| Dec 31, 2021 | 1.01 Mn |
| Sep 30, 2021 | -75,667.00 |
| Jun 30, 2021 | -59,564.00 |
| Mar 31, 2021 | -51,024.00 |
| Dec 31, 2020 | -86,405.00 |
| Sep 30, 2020 | -44,735.00 |